Tubiana-HulinM .1998 .LiechtensteiAn, PorterL. Long-term Pamidronattereatmeontfadvancedmultiplmeyeloma References patientsreducesskeletaelvents:myelomaaredia studygroup. JCiin Oncoi, 16 : 593-602.
Kaye HansenH,S HansenH . .Medical ment. NewYorkO, : .
Foley KM,Samuel H .1993 .Cancerprincipleand prac 21. Ciba-GeigyCorporatioAnr.edia(Pamidronatep)ackage ticeofoncologyP.hiladelphia. , : 2807-41.
Holten-VerzantvoATo .2001 .Pallia breasctancerw:hatto expectin 2001 and beyond. tivePamidronattereatmeinntpatientwsithbonemetas Oncologist, 11 : 491-8.
.1997 .. Geneva.WHO 1996. Cancer, 80(suppl 8) : 1668-73.
Hughes DE,Uy HL .1995 .Bisphosphonates tom prevalencec,haracteristaicnsd distressin a promoteaspoptosiisn maurineosteoclasintvsitro and cancerpopulationQ. JBone MinerBes, 10 : 1478-87.
Shipman CM .1996 .. Apperley JF. Bisphospho OncoiCiinNorthAm, 21 : .
.1988 .factorisn bonematrixC. ibaFoundSymp, 136 : 665-72.